AtriCure, Inc. Announces Pricing of Initial Public Offering of Common Stock.

WEST CHESTER, Ohio -- AtriCure, Inc. (Nasdaq:ATRC) today announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price of $12 per share. AtriCure, Inc. has granted the underwriters a 30-day option to purchase up to an additional 150,000 shares at the initial public offering price to cover over-allotments, if any, and certain selling shareholders have also granted the underwriters an over-allotment option to purchase up to 450,000 shares. AtriCure, Inc. estimates that the gross proceeds from this offering will be approximately $48 million, or approximately $49.8 million if the underwriters exercise their over-allotment option in full. UBS Investment Bank and Piper Jaffray & Co. are acting as joint book-running managers of the offering, and Thomas Weisel Partners LLC and A. G. Edwards & Sons, Inc. are acting as co-managers of the offering.

AtriCure, Inc.'s common stock is scheduled to commence quotation on The NASDAQ National Market under the symbol "ATRC" on August 5, 2005.

The offering is made only by means of a prospectus, copies of which can be obtained from UBS Investment Bank, Attention: Prospectus Dept., 299 Park Avenue, New York, NY 10171 or from Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 4, 2005. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a rapid, irregular quivering of the upper chambers of the heart.